

Grifols inaugurates new state-of-the-art manufacturing plant in Ireland to meet growing global demand for plasma medicines

- **Dublin manufacturing facility triples Grifols' annual filling production capacity of its innovative flexible container, ALBUTEIN FlexBag™, to further address rising demand for albumin, the most abundant plasma protein**
- **Marking the company's 10 years in Dublin, this major expansion also strengthens the site's longstanding role as a global logistics and supply hub thanks to Ireland's diverse and skilled workforce, its strategic location and business-friendly environment**
- **The new plant further reflects Grifols investment in Europe and expands its current global capacity to meet rising demand for plasma medicines**

Barcelona, Spain, Oct. 19, 2022 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma-derived medicines, today will inaugurate a new albumin purification and filling plant at its global manufacturing and supply hub in Dublin, Ireland – a milestone in the continuing expansion of a site that plays an increasingly vital role in producing, packaging and distributing Grifols therapies worldwide.

The newly built plant adds more than 17,000 sq m (183,000 sq ft) to Grifols' cutting-edge Grange Castle facilities, located just outside the Irish capital, and is part of the company's ongoing global growth and investment in critical plasma infrastructure to provide more medicines to more patients in more parts of the world.

It triples the annual filling production capacity of Grifols' flexible container, ALBUTEIN FlexBag™. This container, which comes in several sizes and albumin concentrations, provides an innovative alternative to storing and transporting albumin, as well as administering the therapy to patients.

Global demand for albumin, whether in bags or vials, is expected to increase by a compound annual growth rate of around 5% over the next five years¹. The most abundant protein found in plasma, albumin is used to replace lost fluids, restore vital blood volume and to treat prevalent diseases such as cirrhosis. Grifols is also advancing its potential use to treat neurological degenerative disorders.

Applying the latest eco-efficiency technologies to conserve energy and water, the state-of-the-art albumin manufacturing plant is the latest showcase for Grifols' industry-leading design and engineering. It is the first Grifols plant to be 100% designed by BIM (Building Information Modeling) technology, enabling optimization of resources.

¹ Marketing Research Bureau Report

GRIFOLS

“This new magnificent Dublin manufacturing facility, which incorporates Grifols industry-leading engineering, is indicative of this company’s commitment to investing in essential plasma-medicine infrastructure globally to treat more patients around the world,” said Víctor Grifols Deu and Raimon Grifols, Grifols co-CEOs.

Grifols has invested close to EUR 300 million in its Irish operations since first establishing a presence in the country in 2012. Ireland’s diverse and skilled talent pool, its strategic location between North America and continental Europe and its accommodating business environment have fostered Grifols’ local growth. The company currently has more than 300 employees at its Dublin site, a number expected to grow over the next couple of years to approximately 500.

Dublin is Grifols’ fifth manufacturing site for essential plasma medicines alongside Barcelona; Clayton, North Carolina; and Los Angeles, California, as well as Biotest’s site in Dreieich, Germany. Additional Grifols manufacturing sites under construction will become operational in Montreal, Canada, in 2024, and El Cairo, Egypt, in 2025.

“I very much welcome Grifols’ continued investment in Ireland and the 200 extra jobs this will bring to Dublin,” said Leo Varadkar, Tánaiste and Minister for Enterprise, Trade and Employment. “Having steadily grown its presence in Ireland over the last decade, Grifols’ further expansion reinforces Dublin as an important center of the company’s global operations. It’s further proof of Ireland’s role as a major biopharmaceutical and international trade hub, with a highly talented workforce available.”

For media inquiries:

Grifols Press Office media@grifols.com Tel. +34 571 00 02	FGS Global Email: grifols@fgsglobal.com Tel: +44 20 7251 3801
---	---

Investor contact:

Investor Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com – sustainability@grifols.com

Tel.: +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

GRIFOLS

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 400 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 27,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2021, Grifols' economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [grifols.com](https://www.grifols.com)

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.